Article
Oncology
Seoyul Lee, Wookyeom Yang, Dae Kyoung Kim, Hojun Kim, Minjoo Shin, Kyung Un Choi, Dong Soo Suh, Yun Hak Kim, Tae-Ho Hwang, Jae Ho Kim
Summary: This study found that the oncolytic activity of oncolytic vaccinia virus (OVV) in drug-resistant ovarian cancer is limited. However, by inhibiting MEK, the oncolytic efficacy of OVV in drug-resistant ovarian cancer can be reinforced, possibly through the activation of STAT3 and the downregulation of the cytosolic DNA-sensing pathway.
MOLECULAR THERAPY-ONCOLYTICS
(2022)
Article
Oncology
Tyler D. Hitchman, Gabriella Bayshtok, Emilie Ceraudo, Amanda R. Moore, Cindy Lee, Ruobing Jia, Naitao Wang, Mohini R. Pachai, Alexander N. Shoushtari, Jasmine H. Francis, Youxin Guan, Juliet Chen, Matthew T. Chang, Barry S. Taylor, Thomas P. Sakmar, Thomas Huber, Ping Chi, Yu Chen
Summary: The study found that the combination of Gα(q) and MEK inhibition showed promising therapeutic potential in treating melanoma, suggesting an improved therapeutic strategy for targeting Gα(q) in uveal melanoma.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Zhong-Zhe Lin, Mickey C-T Hu, Chiun Hsu, Yao-Ming Wu, Yen-Shen Lu, Ja-An Annie Ho, Shiou-Hwei Yeh, Pei-Jer Chen, Ann-Lii Cheng
Summary: This study investigated the potential synergism of the telomerase-specific oncolytic adenovirus Telomelysin and the histone deacetylase inhibitor AR42 in treating hepatocellular carcinoma (HCC). Telomelysin and AR42 exhibited synergistic antiproliferative effects in in vitro and in vivo models of HCC. AR42 attenuated the expression of the coxsackievirus and adenovirus receptor and the mRNA levels of human telomerase reverse transcriptase, enhancing the cytotoxicity of Telomelysin.
Article
Immunology
Duo Chen, Luyu Huang, Haiyu Zhou, Yuhui Zhang
Summary: Oncolytic viruses combined with interleukin 10 (IL-10) can enhance antitumor efficacy significantly, especially depending on CD8(+) T cells. The combination therapy induced long-term tumor-specific immune memory in a mouse model, rejecting rechallenge by specific tumor cell lines.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Akimasa Tomida, Shigeki Yagyu, Kayoko Nakamura, Hiroshi Kubo, Kumiko Yamashima, Yozo Nakazawa, Hajime Hosoi, Tomoko Iehara
Summary: Chimeric antigen receptor (CAR)-T cells targeting disialoganglioside (GD2) have shown limited effectiveness in early clinical trials for patients with relapsed/refractory neuroblastoma. This study demonstrates that combination therapy with GD2-CAR-T cells and a MEK inhibitor can enhance antitumor efficacy in neuroblastoma, regardless of the MAPK pathway mutation status in tumor cells. These findings suggest a potential strategy to improve immunotherapy outcomes in patients with neuroblastoma.
Article
Biochemistry & Molecular Biology
Ana Alfano, Eduardo G. A. Cafferata, Mariela Gangemi, Alejandro Nicola Candia, Cristian M. Malnero, Ismael Bermudez, Mauricio Vargas Lopez, Gregorio David Rios, Cecilia Rotondaro, Nicasio Cuneo, David T. Curiel, Osvaldo L. Podhajcer, Maria Veronica Lopez
Summary: More than one million women worldwide are diagnosed with gynecological cancer each year. Most cases are diagnosed at a late stage due to a lack of symptoms or limited access to prevention in low-resource countries. The oncolytic adenovirus AR2011 has shown promising results in inhibiting the growth of ovarian, uterine, and cervical cancers in vitro, as well as synergizing with chemotherapy. In animal models, AR2011 has demonstrated efficacy in treating ovarian cancer and inducing an abscopal effect. It is a potential novel medicine for intraperitoneal disseminated ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biotechnology & Applied Microbiology
Kai Ye, Fan Li, Ruikun Wang, Tianyi Cen, Shiyu Liu, Zhuoqian Zhao, Ruonan Li, Lili Xu, Guanmeng Zhang, Zhaoyuan Xu, Li Deng, Lili Li, Wei Wang, Alexey Stepanov, Yajuan Wan, Yu Guo, Yuanke Li, Yuan Wang, Yujie Tian, Alexander G. Gabibov, Yingbin Yan, Hongkai Zhang
Summary: By infecting tumor cells with a herpes simplex virus 1 (HSV-1)-based oncolytic virus encoding OX40L and IL12, the tumor cells can be transformed into artificial antigen-presenting cells (aAPCs), which provides optimal signals for T cell activation and enhances the effectiveness of tumor-infiltrating lymphocyte (TIL) therapy. The combination of OV-OX40L/IL12 and TIL therapy not only induces complete tumor regression but also elicits an antitumor immunological memory, demonstrating the potential of this combination strategy.
Article
Medicine, Research & Experimental
Xu He, Wei Yao, Ji-Ding Zhu, Xin Jin, Xin-Yuan Liu, Kang-Jian Zhang, Shou-Liang Zhao
Summary: This study investigates the potential of human dental pulp stem cells (hDPSCs) loaded with oncolytic adenovirus for cancer biotherapy. It found that hDPSCs were susceptible to infection by a novel oncolytic adenovirus called YSCH-01 and could transport the virus to tumor sites. The use of hDPSCs as a cell carrier showed potential anti-tumor effects in xenograft models and significantly reduced the required dosage of virus delivery compared to other methods. The supernatant secretome derived from hDPSCs loaded with YSCH-01 exerted a specific anti-tumor effect without toxicity for normal cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Lili Huang, Huaxin Zhao, Mengying Shan, Hong Chen, Bin Xu, Yang He, Yu Zhao, Zhuqing Liu, Jianhua Chen, Qing Xu
Summary: This study found that oncolytic adenovirus enhances the effectiveness of PD-1 antibody therapy in CRC by promoting T cell infiltration into the tumor and improving the immune response. This provides a potential therapeutic strategy for CRC.
Article
Medicine, General & Internal
Priscilla K. Brastianos, Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Shervin Tabrizi, Brian Kabat, Julia Thierauf, Michael W. Ruff, Daniela A. Bota, David A. Reardon, Adam L. Cohen, Macarena I. De La Fuente, Glenn J. Lesser, Jian Campian, Pankaj K. Agarwalla, Priya Kumthekar, Bhupinder Mann, Shivangi Vora, Michael Knopp, A. John Iafrate, William T. Curry, Daniel P. Cahill, Helen A. Shih, Paul D. Brown, Sandro Santagata, Fred G. Barker, Evanthia Galanis
Summary: This study investigated the safety and efficacy of the BRAF-MEK inhibitor combination vemurafenib-cobimetinib in patients with papillary craniopharyngiomas. Results showed that 15 out of 16 patients had a durable objective partial response or better to the therapy. The median reduction in tumor volume was 91%, and the progression-free survival rates at 12 and 24 months were 87% and 58% respectively.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Virology
Lu Long, Jian Gao, Ruiyang Zhang
Summary: In this study, the influence of PTTG1 on the treatment of pancreatic adenocarcinoma (PAAD) was explored. It was found that higher expression of PTTG1 was associated with higher clinical stages and worse prognosis of pancreatic cancer. PTTG1 can enhance the entry of OAd5 virus.
Review
Biochemistry & Molecular Biology
Kaiyi Yang, Shenghui Feng, Zhijun Luo
Summary: Prostate cancer is a common and deadly cancer in males. Androgen-deprivation therapy is effective in early stage tumors, but many cases progress to metastatic castration-resistant prostate cancer. Existing clinical treatments for advanced prostate cancer have limitations, but gene therapy and viral therapy show promise in controlling the disease.
Article
Oncology
Jingshu Xiao, Jiaming Liang, Junjie Fan, Panpan Hou, Xiaodong Li, Haipeng Zhang, Kai Li, Lang Bu, Ping Li, Miao He, Yongheng Zhong, Liping Guo, Penghui Jia, Qiaoqiao Xiao, Junyu Wu, Hong Peng, Chunmei Li, Fan Xing, Deyin Guo
Summary: This study presents a promising strategy for the treatment of aggressive glioblastoma (GBM) by combining CDK4/6 inhibitors with oncolytic viruses (OV). CDK4/6 inhibition enhances the efficacy of OV by promoting autophagic degradation of MAVS, impairing antiviral responses, and amplifying oncolysis. Furthermore, CDK4/6 inhibitors and OV synergistically induce immuno-genic cell death and boost antitumor immunity, inhibiting tumor growth and prolonging survival in GBM models.
Article
Oncology
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y. Bartee, Eric Bartee
Summary: This study generated a doubly recombinant oncolytic virus that expresses PD1 and IL-12 fusion protein to treat solid tumors. The results revealed that the inflammation induced by the virus during therapy has a dual effect, and blocking the TNF pathway can enhance the therapeutic efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Virology
Paola Blanchette, Jose G. Teodoro
Summary: In the 1990s, adenovirus was genetically engineered to selectively destroy cancer cells. Despite slow progress in translating oncolytic adenovirus to the clinic, interest in the virus remains strong. Many clinical trials are currently using recombinant adenovirus.